
 		*		·_*_*_*_*	.*.*.*.*.		********		

	C	Clos	trid	ium	Dif	ficil	е		1. 1. 1. 1.
									and the second
 							•-•-•-		
 			******		17878787878	*******		17 8 7 8 7 8 7 8 7	********
 ********						*******	*******		



What is Clostridium difficile (C-diff)

- A spore forming, Gram-positive anaerobic bacillus
- Produces two exotoxins: toxin A & toxin B
- Common cause of antibiotic-associated diarrhea
- Accounts for 15-25% of all episodes of antibiotic-associated diarrhea

C-diff Facts

- CDI increases hospital length of stay by 2.8-5.5 days¹
- Costs of inpatient CDI in 2008 dollars have been estimated at \$3,006-\$15,297 per episode'
- Patients are twice as likely to be discharged to a long-term care facility'
- Mortality is estimated to be 5-10% leading to an estimated 14,000-20,000 deaths each year'

1. Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. The Society for Healthcare Epidemiology of America, 35, 628-645.

What are the differences between Cdiff colonization & C-diff Infection?

Colonization

- Patient exhibits <u>NO</u> clinical symptoms
- Patient tests positive for Clostridium difficile organism or its toxin
- More common than C-diff
 infection
- Very common in babies and children < one year of age
- Infection

- Patient exhibits clinical symptoms
- Patient tests positive for Clostridium difficile organism or its toxin

Symptoms of C-diff

- Watery diarrhea
- Nausea
- Vomiting
- Abdominal pain/tenderness
- Fever
- Severe infection

C-Diff Pathogenesis

- Exposure to antibiotics disrupts normal microbiota of intestinal tract
- Ingestion of C-difficile spores occurs
 - Usually transmitted from other patients
- Incubation < 7 days-3 months after antibiotic therapy
 - Median time 2-3 days
 - Some cases develop with only one dose of an antibiotic

Transmission

- Spores persist in environment for months
 - Studies show 5 months on hard surfaces
 - Contamination of patient environment
 - Contamination of shared equipment
- **HCP** hands
- HCP cellular phones
 - studies implicate as reservoir

Transmission

- Fecal-oral route
 - Any activity that results in movement of organism into mouth
 - Activities implicated
 - Meals

- Oral care/oral suctioning
- Administration of feedings or meds

Transmission

- Other activities implicated
 - Emergency procedures (i.e. intubation)
- Poor hand hygiene practices
- Sharing of patient care items without appropriate disinfection
- Ineffective environmental cleaning

Sources of C-diff Organism

- Infected humans
 - Symptomatic
 - Asymptomatic carriers

- Newborns
- Children less than one year old • Estimated 3% of healthy, symptom-free adults
- Colonization in hospital inpatients ranges from 7-26% (longer the stay, more likely colonization becomes)
- Long-term care: 5-7% of patients colonized
- Inanimate objects previously contaminated with Clostridium difficile
 - Hard or soft surfaces
 - Shared equipment
- Environmental contamination increases with increasing severity of disease

Risk Factors

- Antibiotic exposure
- Multi class & longer course
 Advanced age

- Most commonly
 - Clindamycin
 - 3rd generation Cephalosporins
 - Fluoroquinolones
 - Exposure to single dose of antibiotic for pre-op prophylaxis has been associated with CDI
- Hospitalization: longer length
- Gastric suppression (PPIs) • Feb2012 FDA communication: Important role in patients with minimal or no ATB exposure

- GI surgery/manipulation
- Gastric suppression
- Immunocompromised
- Steroid use

FY'13-'14 Hospital Acquired C. Diff. Infections – Audit Summary

- 4 23 HAI to date
- Average age = 74
- Average length of stay prior to c. diff + test = 18 days
- 56% on PPI at home, 81% on PPI at GSH
- 100% had prior antibiotic exposure
- 2 patients had only one pre-op dose to prevent SSI

FY'13-'14 Hospital Acquired C. Diff. Infections – Audit Summary

- Class exposure varies
- Antibiotic Combinations

 Audit Summary
Cost sec call call the sec and
43 13 13 13 13 13 13 13 13 13 1



Diagnosis

- Test patients with 3 or more diarrhea stools within 24 hour period
- Some recommend testing diarrhea of >12 hour duration

Lab testing

- PCR technology used at GSH (highly sensitive and specific for presence of toxin producing Clostridium difficile organism
- Only test loose, watery stools
- Do not test for cure
- Routine repeat testing discouraged: do not repeat within 7 days of initial test
- Lab will auto reject if test ordered < 7 days after initial test.

Bristol Stool Chart

 Standardized documentation tool for charting stool consistency

- Accurately describes stool consistency
- Nursing should chart stools of any patient with diarrhea using Bristol Stool chart (currently documented in Shift Summary)
- Lab will test only Type 6 and Type 7 stools





Area to document Bristol Stool Chart

Treatment DC causative antibiotic Metronidazole (Flagyl) Metronidazole (Flagyl) 500mg po every 8 hours for 10 days

- Secreted into colon, not just "passing through" GI tract: 6-15% of dose secreted into bowel
- Vancomycin (oral or rectal)
 - 125mg po every 6 hours for 10 days
 - Results in colon levels of 63-760mcg/g on day 2 & 152-880 mcg/g on day 4
 - Retention enema dose 500mg in 100ml normal saline as retention enema every 6 hours
 - Flexiseal: instill & clamp off for period of time • Use caution if distended colon: risk of perforation
- Fidaxomicin
 - 200mg po bid for 10 days
- Do not give antimotility agents



Severity-Based Treatment*

- Initial episode, mild or moderate disease (fever, leukocytosis < 15,000</p> and serum creatinine <1.5 times baseline) Metronidazole (Flagyl) 500mg PO every 8 hours for 10 days
- Initial episode, severe (fever, leukocytosis > 15,000 or serum creatinine >1.5 times baseline) or moderate with comorbid illness
- Vancomycin 125 mg PO every 6 hours for 10 days OR 250 mg PO every 6 hours for 10 days Initial episode, severe complicated (hypotension or shock and/or known
- or suspected ileus or toxic megacolon)

 Consider Infectious Disease consult or Surgical consult.
 - Vancomycin 500mg PO every 6 hours for 14 days <u>and</u> Metronidazole (Flagyl) 500mg IVPB every 8 hours. Change to oral route when tolerated.
- Securrent episode (re-appearance of CDI within two months of previous episode)
 - Utilize same antibiotic used for initial episode or Fidaxomicin (Dificid) 200mg PO twice daily for 10 days
- * Taken from C-Diff Order Set

What complications result from C-diff infection?

- Pseudomembranous colitis
- Toxic megacolon
- Perforations of the colon
- Sepsis
- Death

Surveillance

- Identify patients with diarrhea
- Implement contact precautions for all patients with diarrhea until C-diff testing completed & C-diff ruled out





Infection Control Practices

- Initially isolate all patients with diarrhea until stool specimen obtained & CDI ruled out
- Contact precautions
 - gown & gloves
- Hand hygiene
 - Use soap & water to mechanically remove spores
 - Place Stop Sign over alcohol hand foam dispenser
 - Note: Spores are not killed by soap & water; <u>MUST</u> mechanically remove them by friction.
 - Do not short change time & friction when washing

Infection Control Practices

- Room cleaning with bleach
- Discontinuation of isolation after 48 hours of formed stools
 - Must have Infection Control approval
 - Patient showers and is moved immediately to clean room
 - Isolation not discontinued if clean room not available

Prevention of Transmission to other patients

- Hand hygiene: Teach <u>all patients, families &</u> <u>visitors</u> to complete hand hygiene
- Teach all family members & visitors to utilize contact precautions in C-diff rooms
- Do not take items from C-diff room out into public area
- Teach families & visitors to perform Hand hygiene when leaving C-diff room

Prevention Tactics

- Limit antibiotic use
 - Decrease time broad spectrum ATBs used
 - Narrow spectrum as soon as organism ID'd
 - Minimize inappropriate duration of therapy
 - De-escalate therapy asap

- Convert from IV to PO antibiotics asap
- Do not treat colonized patients: use antibiotics only for patients with documented infection

Pharmacy Chart Tag

	Pharmaclet Place on Chart for Orders Requiring Physician Response Date: Time: RP Signature:	PHYSICIAN: Check "Y" or "N" for order approval	
REQUEST	 M-PO Switch, Patient to receiving medications crafty or able to take PO. Please change the following parenteral medicational to one route/deese. 		
	4).	1922	No
	10	1993	No
Please Address	ф	Yes 🗆	No
Nursing: Remove this section	2) Reveal Dose Adjustment. Chappe FROMTO Beason, Current BC mand tendingBeBeen Other	Yes 🗖	No
when noting order	B. Culture/Nenalitivity Review. Sources togarians Date: Current Artimiscobukts: December 1.	Yes 🗆	No
Send copy of order		Duration of	Therapy
to Pharmacy	Besistance Disarce spectrum Disug-disg mismatch Temp down x 48-72 tes./ Nag. outsets/ Nag. PedCalchonin C.dif prevention Disarce of therapy	Cays Weeks	
	Other: Convert to HORA (Pepcid) CISTOP RP	1.1.1.1	
	Dute: Time:		
	Physician Signature:		

- Pharmacist recommendation to providers
 Renal dose
- adjustmentsI.V. to PO conversions
- Drug-bug mismatches
- Duration of antibiotic therapy clarifications

Prevention: Pharmacy

- Restriction of certain antibiotic classes
- Formulary changes to promote use of narrow spectrum antibiotics
- Ensure appropriate antibiotic use
- Monitor for narrowing, de-escalation & appropriate duration of therapy
- Provide feedback on adherence to guidelines
- Antimicrobial Stewardship

Cleaning & Disinfection

- 1:10 dilution of bleach solution daily & on discharge
- Focus on high touch surfaces
- Frequency & intensity of cleaning based on patients level of hygiene & degree of environmental contamination (incontinence)
 Nursing should notify EVS of incontinence
- Heaviest contamination bathrooms & floors
- Privacy curtains: are always changed on terminal clean of C-diff room

Cleaning & Disinfection

Clean/disinfect all patient care equipment
 Leave equipment in CDI room

- Note: if unable to leave equipment in room MUST disinfect with bleach wipes
- Reusable equipment cleaned between uses with bleach wipes
- EVS: Monitors cleaning process & samples cleanliness in all CDI rooms

Adequacy of EVS Cleaning

- Dazo routinely used on patient rooms to spot check adequacy of cleaning
- ATP utilized to verify adequacy of cleaning
- Pass if less than 250
- Initial samples done before cleaning with repeat after housekeeper cleaned room

Initial ATP Testing

• 4/1/2014: initial room test: before cleaning

Bedrail: 162

• Pillow: 42

• Floor: 1,071

Sharps - 32

After cleaning:

- RR door knob 59
- Toilet flush 27
- Call light 48 • Bed rail - 22
- Door knob room 63
- Phone 40
- Bed controls at foot of bed - 24
- Light switch 27
- RR grab bar 91
- Floor 89

Repeat ATP Testing

4/4/2014 Room 3225

- Bathroom door knob: 16
- Toilet flush handle: 16
- Nurse call light: 23
- Bedrail: 98
- Door knob (inside room): 27
- Phone: 42
- Sed control (foot of bed): 3537
- Bed control (left side of bed): 81
- Light switch: 51

- 4/4/2014 Room 6203
- Sathroom door knob: 24
- Toilet flush handle: 46 Nurse call light: 46
- Bedrail: 37
- Door knob (inside room): NA
- Phone: NA
- Bed brake pedal: 8356
- Bed control (left side of bed): 36 Light switch: 38
- Grab bar (bathroom): 18
- Sharps container: 52
- Grab bar (bathroom): NA Sharps container: 51

EVS Summary

- On initial testing areas that showed elevated numbers: foot of bed, brake pedal & floor
- Processes intensified with no touch points failing